All In Biotech

Drug Trial Radar · NCT01589978

PROMUS Element Plus US Post-Approval Study

A U.S. Post-Approval Study of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System

Last checked: Nov 20, 2026Latest source record: Jul 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

2,681

Actual

Start

May 2012

Primary completion

Aug 2014

Study completion Jun 2018

Sponsor

Lead sponsor
Boston Scientific CorporationIndustry
Sponsor type
Industry
First posted
May 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice. Patients will have symptomatic heart disease or documented silent ischemia. This is a prospective, open-label consecutively-enrolling study. Clinical follow-up is through 5 years. Approximately 2,689 patients are to be enrolled in up to 65 centers in the United States.

Conditions

  • Coronary Artery Disease

Interventions

  • PROMUS Element Plus Coronary Stent SystemDevice

    PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).

  • AspirinDrug

    Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.

  • P2Y12 antagonistDrug

    Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI. * Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily) * Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling) * Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided. * Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cardiac Death or Myocardial Infarction Rate in PLATINUM-like PatientsTime frame: 12 months

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • Huntsville Hospital - The Heart Center, PC

    Huntsville, Alabama

  • Springhill Medical Center

    Mobile, Alabama

  • NEA Baptist Memorial Hospital

    Jonesboro, Arkansas

  • St. Bernard's Medical Center

    Jonesboro, Arkansas

  • Loma Linda University Medical Center

    Loma Linda, California

  • Mercy General Hospital

    Sacramento, California

  • Christiana Hospital

    Newark, Delaware

  • Brandon Regional Hospital

    Brandon, Florida

  • North Florida Regional Medical Center

    Gainesville, Florida

  • Memorial Regional Hospital

    Hollywood, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Orlando Regional Medical Center

    Orlando, Florida

  • Bay Medical Center

    Panama City, Florida

  • Martin Memorial Health Systems - Martin Memorial Medical Center

    Stuart, Florida

  • Piedmont Hospital

    Atlanta, Georgia

  • Coliseum Medical Center

    Macon, Georgia

  • Redmond Regional Medical Center

    Rome, Georgia

  • Blessing Hospital

    Quincy, Illinois

  • IU Health North Medical Center

    Carmel, Indiana

  • Franciscan St. Francis Hospital

    Indianapolis, Indiana

  • Community Heart and Vascular Hospital

    Indianapolis, Indiana

  • St. Joseph Hospital

    Lexington, Kentucky

  • Cardiovascular Research, LLC

    Shreveport, Louisiana

  • Eastern Maine Medical Center

    Bangor, Maine

  • Cape Cod Hospital

    Hyannis, Massachusetts

  • Lakeland Hospitals at St. Joseph

    Saint Joseph, Michigan

  • Mercy Hospital

    Coon Rapids, Minnesota

  • North Memorial Medical Center

    Minneapolis, Minnesota

  • United Hospital - St. Paul Heart Clinic

    Saint Paul, Minnesota

  • Forest County General Hospital

    Hattiesburg, Mississippi

  • St. John's Regional Health Center (Springfield)

    Springfield, Missouri

  • Cox Medical Centers

    Springfield, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • New York University Medical Center

    New York, New York

  • St. Elizabeth Medical Center

    Utica, New York

  • Novant Health Presbyterian Medical Center

    Charlotte, North Carolina

  • St. Francis Hospital

    Tulsa, Oklahoma

  • Doylestown Hospital

    Doylestown, Pennsylvania

  • Presbyterian University of Pennsylvania Medical Center

    Philadelphia, Pennsylvania

  • University Medical Center-Greenville Memorial Hospital

    Greenville, South Carolina

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.